Research programme: CAR-T cell based therapeutics - Autolus

Drug Profile

Research programme: CAR-T cell based therapeutics - Autolus

Alternative Names: Dominant negative SHP2 protein engineered CAR T-cells - Autolus; Engineered T-cell immunotherapeutics- Autolus

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University College London
  • Developer Autolus
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple myeloma; T cell lymphoma

Most Recent Events

  • 22 Mar 2017 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the American Society of Hematology 58th Annual Meeting (ASH-Hem-2016)
  • 21 Mar 2017 CAR-T cell based therapeutics - Autolus is available for licensing as of 21 Mar 2017. http://www.autolus.com/about-us/overview
  • 04 Dec 2016 Preclinical trials in Multiple myeloma in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top